Object of the present invention is a drug delivery system comprising a decellularized corneal stroma scaffold having dispersed within and/or bound to its surface microparticles containing at least one pharmaceutically active molecule dispersed in a matrix having a composition consisting for at least 70% of polylactic co-glycolic acid (PLGA).

Methods and compositions for tissue regeneration of the present invention include a biocompatible porous composite of a decellularized tissue and an aptamer-functionalized hydrogel, wherein the aptamers of the aptamer-functionalized hydrogel specifically and reversibly bind to an active agent.

Disclosed herein are compositions and methods to decellularize an isolated organ or portion thereof. Also disclosed herein are compositions and methods for treatment of disease utilizing a decellularized or recellularized organ. Also disclosed herein are methods of improving decellularization and/or recellularization of an isolated organ or portion thereof.

A delivery device or patch is disclosed that includes a detachable hybrid microneedle depot (d-HMND) for cell delivery. The system includes, in one embodiment, an array of microneedles formed from an outer PLGA shell and an internal gelatin methacryloyl (GelMA)-mesenchymal stem cells (MSC) mixture (GMM). The array of microneedles project from a base substrate layer that may be flexible. The therapeutic device may be applied to a tissue site of interest and the base substrate layer is removed leaving the hybrid microneedles in the tissue at the site of application to deliver MSCs. Other stem/therapeutic cells may also be delivered with the hybrid microneedles.

A method for producing xenogeneic bone graft, which is a material for use in bone tissue therapy, is provided. The method includes the steps of isolating the cancellous bones from cartilage and cortical bone by fragmenting them into pieces, washing the bone fragments with purified water to partially remove the organic phases and boiling them with purified water, contacting the bone fragments with a solvent for further removal/isolation of the organic phase, washing the bone fragments to remove the solvents used and other possible residues, subjecting them to a hydrothermal and/or solvothermal treatment with a solvent at a pressure of more than 1 atm and a temperature in the range of 100° C. to 300° C., after which washing them with purified water, and drying the cancellous bone fragments, for example, at a temperature in the range of 50° C. to 100° C. to dehydrate them.

A method for preparing a biological material for implanting provides irradiating at least a portion of the surface of the material with an accelerated Neutral Beam.

The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular tissue matrices for treatment of a breast.

The present disclosure relates to tissue engineering, and more particularly to a method for treating or repairing rotator cuff or other tendon tears or damage using scaffold-free 3-dimensional engineered tendon constructs.

A method and system for making a bone plug using cortical bone material. A patient jaw having insufficient bone at a surgical site may be scanned to provide a 3D image which may be used to design a virtual bone plug and to fabricate the bone plug for placement within the patient. The bone plug may be formed from cortical bone that can be reconstituted and demineralized or demineralized and milled to shape.

A method of lamellar corneal graft implantation is disclosed herein. In one or more embodiments, the method includes the steps of: (i) modifying a genetic component of a lamellar cornea or other tissue of an animal so that the lamellar cornea or other tissue of the animal can be used for human transplantation; (ii) decellularizing the lamellar cornea or other tissue ex vivo using chemical means; (iii) modifying a shape of the lamellar cornea or other tissue before or after transplantation; and (iv) applying a photosensitizer and ultraviolet radiation to the lamellar cornea or other tissue so as to crosslink collagen and intercellular proteins of the lamellar cornea or other tissue, kill the cells exposed to the photosensitizer, and eliminate an immune response by a host to the implanted lamellar cornea or the tissue.